Information Provided By: 
Fly News Breaks for May 10, 2019
MDT, AXNX
May 10, 2019 | 07:15 EDT
SunTrust analyst Bruce Nudell raised his price target on Axonics (AXNX) to $33 and kept his Buy rating after its Q1 earnings, saying the results have strengthened his bullish outlook on the stock based on the company's increased market share gains for its sacral neuromodulation device. The analyst anticipates a "rapid share shift" given the device's value proposition - including ability to have a full body MRI and fewer replacements over a 15-year period - over Medtronic's (MDT) "outdated" Interstim II.
News For AXNX;MDT From the Last 2 Days
There are no results for your query AXNX;MDT
